A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: c2fad774785d75533d278a2df224c6bdefcee3b3
First added on: Feb 16, 2025